Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182988 | 1.00 | USP30 (0.38) | USP30CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL19935895 | 1.00 | USP30 (0.38) | USP30CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL4887916 | 1.00 | USP30 (0.38) | USP30CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL25172608 | 0.82 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL28381934 | 0.82 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL12543898 | 0.82 | P2RX7 (0.35) | P2RX7MAPK1 | |
| SCHEMBL19078451 | 0.82 | USP30 (0.38) | USP30AAK1P2RX7BUB1USP2 | |
| SCHEMBL12461395 | 0.80 | USP30 (0.39) | USP30P2RX7HSD11B1USP2SMN1; SMN2 | |
| SCHEMBL21340355 | 0.80 | USP30 (0.39) | USP30P2RX7HSD11B1USP2SMN1; SMN2 | |
| SCHEMBL16272001 | 0.80 | USP30 (0.39) | USP30P2RX7HSD11B1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20240002375-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE | REMIX THERAPEUTICS INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4110459-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4001273-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11110090-B2 | Aminopyrimidines as ALK inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200330464-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-10-22 | — | — | US | disclosed |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2018044767-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | USP30 3757/4885CHRM2 4621/4885CHRM1 3909/4885 |
| US-20240002375-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE | POLRMT, HNRNPA1, SNRPA | USP30 4804/4885CHRM2 4850/4885CHRM1 4758/4885 |
| US-20200330464-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | ALK, RET, BRAF | USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885 |
| US-11110090-B2 | Aminopyrimidines as ALK inhibitors | ALK, RET, BRAF | USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885 |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | ALK, RET, BRAF | USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885 |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | ALK, RET, BRAF | USP30 3040/4885CHRM2 1053/4885CHRM1 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.